Accounting Analysis: Assessing Accounting Quality And Financial Statements

Answer:
Research and development
Research and development and commercialization spending accounted for 45% of the total expenditure of the cluster for the fiscal year 2017/2018, compared to 40% for the financial year 2016/2017. This costs that are comprised of study costs for the clinic, drug formation research and manufacture and distribution fee, regulatory and research fee, and development and commercialization overheads. (Clinuvel Pharmac…